Bharat Biotech and Alopexx Partner to Combat Infectious Diseases

Bharat Biotech has teamed up with Alopexx, Inc. to co-develop and commercialize AV0328, a broad-spectrum antimicrobial vaccine, in India and other low-income countries. The collaboration involves an upfront payment and milestone payments to Alopexx, along with royalties from future sales in licensed regions.

Bharat Biotech announced a partnership with Alopexx, Inc. on Wednesday, aimed at co-developing and commercializing the broad-spectrum antimicrobial vaccine AV0328 in India and low-income countries.

According to a press release from the Hyderabad-based vaccine manufacturer, the collaboration targets poly N-acetyl glucosamine (PNAG) through a synthetic vaccine, aiming to curb antimicrobial resistance.

As part of the deal, Alopexx will receive an upfront payment, milestone payments, and royalties on future sales of AV0328 in the licensed territories.

'We are proud to collaborate with Alopexx to bring AV0328 to regions where it's most needed,' said Krishna Ella, Executive Chairman of Bharat Biotech.

Daniel Vlock, CEO of Alopexx, stated, 'This collaboration brings us closer to addressing the need for affordable, broad-spectrum antimicrobial solutions in low- and middle-income countries.'

(With inputs from agencies.)